TGTX — TG Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.57bn
- $8.77bn
- $616.29m
TG Therapeutics rises after preliminary Q4 net product revenue tops estimates
U.S. RESEARCH ROUNDUP-Domino's Pizza, Elastic NV, Snowflake
Brief: TG Therapeutics Reports Q3 Results And Raises Briumvi® Annual Revenue Guidance
TG Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
TG Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Tg Therapeutics - On Aug 2, Co Entered Into Term Loan Facility Of $250 Million
TG Therapeutics up after raising FY sales forecast for its multiple sclerosis drug
TG Therapeutics Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: CALSTRS Says Withholding Its Votes Concerning Re-Election Of Six Directors At TG Therapeutics' Annual Meeting On June 14
TG Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TG Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: TG Therapeutics Announces Additional Data Presentations For Briumvi
Brief: TG Therapeutics Announces Presentation of Data for BRIUMVI
TG Therapeutics jumps after Q4 rev tops estimates
TG Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI
TG Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: TG Therapeutics Announces European Launch of BRIUMVI (ublituximab-xiiy)
TG Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview